Roundup Lawsuit Advertising: $16B Paid, $7.25B Pending, and the Supreme Court Wildcard

$16 billion. That’s what Bayer has committed to Roundup litigation. And it still isn’t over.

Sixty-five thousand cases remain. A $7.25 billion class settlement is pending final approval. And the Supreme Court is about to decide whether the whole thing dies.

Roundup is the longest-running mass tort in active litigation. It’s also the most uncertain. Two events in the next four months determine everything.

The MDL

MDL 2741 sits in the Northern District of California under Judge Vince Chhabria. It’s been there since October 2016. Ten years.

About 100,000 claims resolved through the initial $10.9 billion global settlement in 2020. Roughly 65,000 remain active across federal and state courts. The federal MDL itself has about 4,500 pending cases.

Bayer’s trial record tells the story of a tort that won’t go away. Nine wins, nine losses across 18 trials. The jury verdicts are staggering.

Johnson v. Monsanto: $289 million (reduced to $20.5 million). Pilliod: $2.055 billion (reduced to $86.7 million). Hardeman: $80 million (reduced to $25 million). McKivison in 2025: $2.1 billion, pending appeal.

Bayer wins some. Loses some. The ones they lose produce headlines that generate leads.

The Settlement Math

Three rounds of settlement define this tort’s economics.

Round 1: The $10.9 billion global settlement in June 2020. Resolved roughly 100,000 claims. Average payout: approximately $100,000 per plaintiff. Tiered from a few thousand (lowest severity) to $250,000+ (terminal NHL).

Round 2: Continued individual settlements through 2021-2025. Bayer added $1.37 billion to litigation reserves in August 2025 alone. Total reserves: over $16 billion.

Round 3: The $7.25 billion class settlement announced February 17, 2026. Preliminary approval March 4. Final approval hearing July 2026.

This isn’t just for the 65,000 existing claimants. It covers future NHL claims from people already exposed who haven’t been diagnosed yet. Structured as declining capped payments over 21 years. Individual payouts up to $165,000 based on usage, disease severity, and age.

Two groups of firms representing 20,000+ claimants have raised concerns. The restrictions on future claims are the sticking point.

The Lead Economics

Roundup CPAs have matured. Not cheap, not explosive.

Raw leads run $265-$375. Signed retainers cost $2,500-$3,500. The qualification rate sits around 8-12%, which is tight. Not every NHL patient used Roundup. Not every Roundup user got NHL.

The settlement value math still works. Even at the lowest tier ($50,000 case on a $3,000 lead), that’s a 17:1 return. At tier 1 ($200,000+ for terminal NHL), it’s 67:1 or better.

But here’s the catch. The $7.25 billion class settlement caps individual payouts at $165,000. For firms holding cases worth $200,000+ in individual litigation, the class deal might not be the best outcome.

That tension is why opt-outs matter. If enough plaintiffs opt out, Bayer walks. CEO Bill Anderson said the “vast majority” must participate.

The Supreme Court Wildcard

Everything above assumes the litigation continues. One case could end it.

Durnell v. Monsanto asks whether FIFRA, the federal pesticide law, preempts state failure-to-warn claims. Bayer’s argument: the EPA determined glyphosate isn’t likely carcinogenic and doesn’t require a cancer warning. State courts can’t override that.

Oral arguments: April 27, 2026. Decision expected by end of June.

In December 2025, the US Solicitor General urged the Court to hear the case. That’s a significant signal favoring Bayer.

If Bayer wins, most pending Roundup lawsuits die. The FIFRA preemption argument would eliminate state-law failure-to-warn claims nationwide. The $7.25 billion settlement becomes unnecessary.

If Bayer loses, the settlement proceeds. The existing litigation continues. The lead market stabilizes.

Two scenarios. Completely different outcomes. Nobody’s advertising heavily into that uncertainty.

The Science Split

The central scientific dispute hasn’t changed since 2015.

The WHO International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans” (Group 2A) in 2015. That classification still stands.

The EPA maintains glyphosate is “not likely to be carcinogenic to humans.”

Every trial turns on this split. Plaintiffs cite IARC. Defense cites EPA. Juries decide.

A key study supporting the EPA’s position was retracted in January 2026. That’s relevant for any cases going to trial after the Supreme Court ruling.

Meta-analyses suggest glyphosate exposure approximately doubles NHL risk and may triple the risk of B-cell lymphomas specifically. Those numbers are what keep the plaintiff pipeline alive.

Who Used Roundup

The exposure pool is enormous. Roundup was the number one selling herbicide in the US for decades. Over 200 million pounds of glyphosate applied annually on American farms.

CDC data shows 70-82% of the US population tests positive for glyphosate exposure, though most is dietary, not direct product use.

The cases that qualify require direct application. Agricultural workers with 80+ hours of lifetime exposure. Residential users with 150+ hours on three or more acres. Diagnosis of NHL under age 70, at least two years after exposure began.

Bayer stopped selling glyphosate-based Roundup for residential use in 2023. Agricultural products still contain it. That move cut off the primary source of future plaintiffs but doesn’t affect the 65,000 existing cases.

The Advertising Picture

Roundup fell off the Whitehardt Hot Tort Report entirely. Not in the top 10 for February 2026.

At its advertising peak (2019-2021), the tort generated heavy spend on social and search. Meta dominated the channel mix. The plaintiff demographic skewed younger and more digitally active than traditional mass tort populations.

Current advertising is minimal. The $7.25 billion class settlement announcement and the pending Supreme Court case created a double pause. Firms are either cashing out existing inventory or waiting for clarity.

The channel mix during active advertising was roughly 40% social, 25% search, 20% broadcast, and 5% CTV. Streaming was underused. It still is, for the firms that are still running.

Qualification Criteria

The screening bar is specific. NHL or related blood cancers (B-cell lymphoma, CLL, follicular lymphoma, DLBCL, mantle cell, marginal zone). Diagnosed at age 70 or younger.

Direct Roundup exposure is required. Agricultural or commercial use means 80+ hours of lifetime application. Residential use means 150+ hours on property of three or more acres.

Minimum two-year latency between first exposure and diagnosis. Five or more years preferred.

Disqualifiers: Agent Orange exposure, prior cancer before NHL diagnosis, HIV/AIDS diagnosis. No deceased cases. Valid US SSN. Not currently represented.

The strongest cases are agricultural workers, landscapers, and groundskeepers with years of documented occupational exposure and terminal NHL.

The Play

Roundup is a wait-and-see tort right now. Two decisions in the next four months change everything.

First, if you’re holding Roundup cases, evaluate the $7.25 billion class deal against your individual case values. The $165,000 cap might be acceptable for lower-tier cases. It’s a loss for severe NHL with documented occupational exposure worth $200,000+.

Second, track the Supreme Court. If Bayer loses Durnell on April 27, the class settlement proceeds and the litigation has a defined endpoint. If Bayer wins, everything changes overnight.

Third, don’t start new advertising until June. The combined uncertainty of the class settlement final approval (July) and the Supreme Court ruling (June) makes new spend a coin flip.

The firms that built Roundup portfolios early own cases worth $50,000-$250,000 each. They paid $3,000 a lead. The ROI math worked. It still works for existing inventory.

But the window for new acquisition closed months ago. This tort belongs to the firms that showed up before the class settlement froze the market.

References

1. In Re: Roundup Products Liability Litigation, MDL No. 2741, N.D. California
2. Reuters. Bayer proposes $7.25B class settlement for Roundup claims, February 2026
3. IARC Monograph on Glyphosate. WHO International Agency for Research on Cancer, 2015
4. Bayer AG. Litigation Update and Financial Reserves, August 2025
5. Durnell v. Monsanto Company, No. 23-1019. US Supreme Court, cert. granted 2025